Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk
about
sameAs
Should hypertensive patients take aspirin? A report from the Food and Drug AdministrationSouth African hypertension practice guideline 2014.Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectiveIdentifying Individuals at Risk for Cardiovascular Events Across the Spectrum of Blood Pressure Levels.Protocol for assessing the hypotensive effect of evening administration of acetylsalicylic acid: study protocol for a randomized, cross-over controlled trial.Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension.Antiplatelet treatment in the secondary prevention of coronary and cerebrovascular disease: is there any place for novel agents?Beneficial effects of low-dose aspirin on aortic stiffness in hypertensive patients.Platelet activation in essential hypertension: implications for antiplatelet treatment.European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituteEuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constitutedReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document2007 ESH‐ESC Guidelines for the management of arterial hypertension
P2860
Q28167669-555902C1-19A3-4E9A-8FA2-1C252C2AF70CQ35081241-7FF573BA-DF21-4568-BB1E-DB24FBD6AD1BQ35793619-0E2A9F80-4960-43A7-84A2-F6CF8CDFF2F3Q36141817-4DC0C563-931E-4C8F-8F36-576C64590EF7Q37113359-26CEFF49-AAC1-46FA-BF47-0CB8065557AAQ38011618-9ACB29C1-0C99-455C-BEDF-323451485C8EQ38130659-8FD1A3B0-3806-42A9-A1FB-CBAB43D7F51AQ39104909-E3AE7417-A548-4911-8969-E0F9F40D9764Q43186392-4C1DC2ED-2E57-48D2-83BF-4B6AC6F24D6CQ48525600-9969C5EC-4CF4-48EF-B024-B6101DDF01CAQ48526535-CD7FEEBE-42E8-47C4-8A34-63A3C5114F18Q56970710-E9495C23-FBF2-4243-B271-7AECF762F5ADQ56970799-5F475344-6D40-49EC-BE42-C253E3CF62A9
P2860
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@ast
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@en
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@nl
type
label
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@ast
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@en
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@nl
prefLabel
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@ast
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@en
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@nl
P2093
P1476
Benefit and harm of low-dose a ...... t baseline cardiovascular risk
@en
P2093
Alberto Zanchetti
Hans Wedel
Ingrid Warnold
Joël Ménard
Lennart Hansson
Stevo Julius
P304
P356
10.1097/00004872-200211000-00031
P407
P50
P577
2002-11-01T00:00:00Z